Additionally, high TIGD1 expression correlated positively with tumor mutation burden in LUAD, KIPAN, and KIRC, as well as microsatellite instability in CESC, LUAD, and BRCA, indicating a potential role for TIGD1 in immune checkpoint blockade therapy response. Here, TIGD1 is linked to neoplasm.